The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index; none of the 31 sources its claims cite is checked for support yet.
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
Open accessAbstract
Hepatic steatosis is a core feature of the metabolic syndrome and type 2 diabetes and leads to hepatic insulin resistance. Malonyl-CoA, generated by acetyl-CoA carboxylases 1 and 2 (Acc1 and Acc2), is a key regulator of both mitochondrial fatty acid oxidation and fat synthesis. We used a diet-induced rat model of nonalcoholic fatty liver disease (NAFLD) and hepatic insulin resistance to explore the impact of suppressing Acc1, Acc2, or both Acc1 and Acc2 on hepatic lipid levels and insulin sensitivity. While suppression of Acc1 or Acc2 expression with antisense oligonucleotides (ASOs) increased fat oxidation in rat hepatocytes, suppression of both enzymes with a single ASO was significantly more effective in promoting fat oxidation. Suppression of Acc1 also inhibited lipogenesis whereas Acc2 reduction had no effect on lipogenesis. In rats with NAFLD, suppression of both enzymes with a single ASO was required to significantly reduce hepatic malonyl-CoA levels in vivo, lower hepatic lipids (long-chain acyl-CoAs, diacylglycerol, and triglycerides), and improve hepatic insulin sensitivity. Plasma ketones were significantly elevated compared with controls in the fed state but not in the fasting state, indicating that lowering Acc1 and -2 expression increases hepatic fat oxidation specifically in the fed state. These studies suggest that pharmacological inhibition of Acc1 and -2 may be a novel approach in the treatment of NAFLD and hepatic insulin resistance.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In high-fat-fed rats with diet-induced hepatic steatosis and insulin resistance, antisense oligonucleotide knockdown of both Acc1 and Acc2 lowered hepatic malonyl-CoA and lipids and improved hepatic insulin sensitivity. The data suggest combined Acc1/Acc2 inhibition may be a therapeutic strategy for NAFLD and hepatic insulin resistance.
Key findings
- Combined Acc1 and -2 ASO reduced hepatic ACC1 and ACC2 mRNA by approximately 80% and total Acc protein by approximately 90%, and lowered malonyl-CoA by 49% (P < 0.05) in refed rat liver; Acc1 or Acc2 ASO alone did not significantly alter malonyl-CoA.
- In high-fat-fed rats, Acc1 and -2 ASO reduced hepatic triglycerides by 45% (P < 0.05), diacylglycerol by 30% (P < 0.05), and long-chain acyl-CoAs by 26% (P = 0.13), and increased fed-state plasma ketones by 83% (P < 0.05) but not fasting ketones.
- Hyperinsulinemic-euglycemic clamps showed Acc1 and -2 ASO increased glucose infusion rates and insulin-mediated suppression of endogenous glucose production, without changing peripheral glucose metabolism; neither Acc1 nor Acc2 ASO alone significantly altered insulin sensitivity, and Acc1 and -2 ASO did not alter insulin sensitivity in chow-fed rats.
- In primary rat hepatocytes, reducing either Acc1 or Acc2 increased fat oxidation, with Acc2 having a greater effect and combined knockdown being synergistic; lipogenesis was inhibited only by Acc1 and combined Acc1 and -2 ASOs, not by Acc2 alone.
Methods
- Male Sprague-Dawley rats were fed chow or a high-fat diet (26% carbohydrate/59% fat/15% protein calories; safflower oil as major constituent); ASO therapy began 3 days after high-fat diet and was given i.p. at 50 mg/kg/wk for 4 weeks.
- Primary rat hepatocytes were transfected with ASO (150 nM) and Lipofectin and assayed for [14C]oleate oxidation and [3H]glycerol incorporation into triglycerides.
- In vivo metabolic assessment used hyperinsulinemic-euglycemic clamps with radioisotope infusions, plus RT-PCR, Western blot, lipid and malonyl-CoA measurements by LC/MS/MS; data analyzed by two-tailed Student’s t tests or 1-way ANOVA with Tukey HSD, significance at P < 0.05.
Limitations
- The paper states that liver-specific Acc reduction did not lower body weight and that longer treatment might be needed for weight reduction; it also notes that ASOs did not alter hypothalamic target expression and no food-intake differences were detected.
- The paper notes prior-model limitations: ACC2-null mice are substantially leaner than wild-type controls, making direct liver effects difficult to discern, and ACC1-null mice are embryonic lethal while ACC1+/- mice appear to have normal hepatocyte Acc1 protein levels.
- Evident from the text: experiments used male Sprague-Dawley rats only, a 4-week high-fat diet model, and small group sizes (often 4–6 rats per group; 6–9 in clamp studies), with no human data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 31 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These changes were associated with increased insulin-stimulated Akt2 activity (Figure 5D)”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Effect of Acc1 and -2 ASO treatment on hepatic insulin signaling.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In rats with NAFLD, suppression of both enzymes with a single ASO was required to significantly reduce hepatic malonyl-CoA levels in vivo, lower hepatic lipids (long-chain acyl-CoAs, diacylglycerol, and triglycerides), and improve hepatic insulin sensitivity.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting malonyl-CoA levels, which are lower than those in refed rat livers, were similar in all groups (data not shown).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Suppression of Acc1 also inhibited lipogenesis whereas Acc2 reduction had no effect on lipogenesis.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In comparison with ASOctrl, Acc1 and Acc2 ASO treatment reduced ACC1 (Figure 1A) and ACC2 mRNA (Figure 1B) levels, respectively, by approximately 80% in the liver.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Acc1 and -2 ASO therapy significantly reduced hepatic glucose production (HGP) during the hyperinsulinemic phase of the hyperinsulinemic-euglycemic clamp (Figure 5, A and B)”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Effect of Acc1 and -2 ASO treatment on hepatic insulin signaling.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Glucose infusion rates were significantly higher in Acc1 and -2 ASO-treated high-fat-fed rats than in the ASOctrl group (Figure 4A).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc1 and -2 ASO reduces hepatic steatosis.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In vitro fat synthesis was significantly inhibited only by the Acc1 and Acc1 and -2 ASOs (Figure 2, B and C)”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the ability of insulin to suppress endogenous glucose production was significantly increased by Acc1 and -2 ASO treatment (Figure 4C).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc1 and -2 ASO reduces hepatic steatosis.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While suppression of Acc1 or Acc2 expression with antisense oligonucleotides (ASOs) increased fat oxidation in rat hepatocytes, suppression of both enzymes with a single ASO was significantly more effective in promoting fat oxidation.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 22
- Probably not a substantial claim. 17
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neither the Acc1 nor the Acc2 ASO significantly altered insulin sensitivity (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI27300DS1).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc1 and -2 ASO reduces hepatic steatosis.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma ketones were significantly elevated compared with controls in the fed state but not in the fasting state, indicating that lowering Acc1 and -2 expression increases hepatic fat oxidation specifically in the fed state.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Malonyl-CoA levels were not significantly altered by Acc1 or Acc2 ASO therapy, whereas the Acc1 and -2 ASO substantially lowered (49%, P < 0.05) malonyl-CoA levels in the liver of refed rats”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Western blot analysis of liver protein extracts from rats injected with the Acc1, Acc2, and combined Acc1 and -2 ASOs confirmed isoform-selective knockdown of Acc protein expression and approximately 90% knockdown of total Acc protein with the Acc1 and -2 ASO (Figure 1E).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ASO-induced inhibition of Acc2 in rat hepatocytes significantly increased fat oxidation without altering malonyl-CoA levels in tissue extracts”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effects were both isoform specific and tissue selective, and there was no apparent compensatory increase in the nontargeted isoform”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Acc ASOs also reduced ACC expression in adipose tissue (∼80%, data not shown) but not in muscle.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“lowering Acc expression in adipose tissue did not alter epididymal fat-pad weight, body weight, plasma-free fatty acids, or 2-deoxyglucose uptake in adipose tissue (data not shown).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Overexpressing lipoprotein lipase (LPL) in the liver in mice results in fatty liver and liver-specific insulin resistance (5).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [5]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“We have also shown that moderate weight loss in humans with type 2 diabetes lowers liver TGs and specifically improves hepatic insulin sensitivity (7).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [7]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The most common disorder associated with NAFLD is insulin resistance, an association which holds true in both lean and obese subjects (3,4).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [3]
- Not checked yetcites [4]
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Short-term high-fat feeding in rats leads to hepatic steatosis, impaired insulin signaling, and hepatic insulin resistance, and reducing lipid accumulation with a mitochondrial uncoupling agent (2,4-dinitrophenol) improves hepatic insulin sensitivity (6).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [6]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Acetyl-CoA carboxylase (Acc) catalyzes the synthesis of malonyl-CoA, which is both an intermediate in fatty acid synthesis and an allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1) (8,9).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [8]
- Not checked yetcites [9]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“They also suggest that reducing liver lipid accumulation may be an attractive therapeutic strategy for NAFLD and type 2 diabetes.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
None of the sources cited for this claim have been checked yet.
In the paper
“Acetyl-CoA carboxylase (Acc) catalyzes the synthesis of malonyl-CoA, which is both an intermediate in fatty acid synthesis and an allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1) (8,9).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [8]
- Not checked yetcites [9]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Short-term high-fat feeding in rats leads to hepatic steatosis, impaired insulin signaling, and hepatic insulin resistance, and reducing lipid accumulation with a mitochondrial uncoupling agent (2,4-dinitrophenol) improves hepatic insulin sensitivity (6).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [6]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Caloric intake and weight gain were similar in all treated groups and did not differ from those of high-fat-fed rats injected with saline.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The reduction in leptin levels during the fed state probably reflects the lower insulin levels (16).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc1 and -2 ASO reduces hepatic steatosis.
What the sources say
- Not checked yetcites [16]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“ACC2-null mice (ACC2 -/-) are leaner than wild-type controls due to increased fat oxidation in heart and skeletal muscle (12).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [12]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Interestingly, hepatic fat oxidation was also increased and hepatic steatosis decreased in ACC2 -/-mice despite normal malonyl-CoA levels; the authors postulated that this might have been a consequence of localized lowering of malonyl-CoA”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [12]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“ACC1-null mice are embryonic lethal (14).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [14]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The primary structural difference between the 2 is an extra N terminal hydrophobic domain in Acc2 that appears to facilitate Acc2 localization to the mitochondrial membrane (13), where it is believed to regulate local malonyl-CoA levels, CPT1 activity, and fat oxidation.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [13]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“There are 2 isoforms of Acc in rodents and humans; Acc1 is highly expressed in liver and adipose tissue whereas Acc2 is predominantly expressed in heart and skeletal muscle and, to a lesser extent, in the liver (12).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [12]
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“The primary structural difference between the 2 is an extra N terminal hydrophobic domain in Acc2 that appears to facilitate Acc2 localization to the mitochondrial membrane (13), where it is believed to regulate local malonyl-CoA levels, CPT1 activity, and fat oxidation.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Introduction
What the sources say
- Not checked yetcites [13]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggesting that Acc2 is solely involved in regulating fat oxidation whereas Acc1 contributes to the regulation of both fat synthesis and fat oxidation in hepatocytes.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc ASOs decrease Acc expression and lower malonyl-CoA levels in rat livers.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Acc2 regulates malonyl-CoA levels in the immediate proximity of CPT1.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Caloric intake, total weight gain, and epididymal fat pad weight were similar in all treated groups (Table 1) and did not differ from those of high-fat-fed rats injected with saline (data not shown).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Acc1 and -2 ASO reduces hepatic steatosis.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“malonyl-CoA produced by Acc1 appears to regulate both fatty acid synthesis and fatty acid oxidation, whereas Acc2 is solely involved in regulating mitochondrial fat oxidation”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
What the sources say
- Not checked yetcites [14]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The adiponectin kit was primarily designed to measure mouse adiponectin, but showed significant cross-reactivity with rat adiponectin.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Biochemical analysis and calculations.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“We have previously shown that this diet produces hepatic steatosis and hepatic insulin resistance within 3 days (6).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Animals.
What the sources say
- Not checked yetcites [6]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with time a relatively modest increase in fat oxidation in the fed state results in lower liver lipid levels and improved hepatic insulin sensitivity”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“It does not have perfect complementarity to any known gene in public databases.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Selection of rat ACC ASOs.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The Yale Animal Care and Use Committee approved all protocols.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Animals.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This chimeric design has been shown to provide both increased nuclease resistance and mRNA affinity while maintaining the robust RNase H terminating mechanism utilized by these types of ASOs (35).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Selection of rat ACC ASOs.
What the sources say
- Not checked yetcites [35]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“It is becoming increasingly clear that hepatic lipid accumulation causes hepatic insulin resistance and contributes to the pathogenesis of type 2 diabetes (2).”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Discussion
What the sources say
- Not checked yetcites [2]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All rats were maintained in accordance with the institutional Animal Use and Care Committees of Yale University School of Medicine.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Animals.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“which promotes nuclear exclusion of Foxo1, thereby lowering its transcriptional activity on the promoters of gluconeogenic genes, such as PEPCK and G6P.”
§ Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 > Statistics.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
ACC1 and ACC2 exhibit considerable sequence identity (~85% excluding the N terminal extension of ACC2) and have the same domain structure responsible for enzyme activity.
“Despite being encoded by separate genes, ACC1 and ACC2 exhibit considerable sequence identity (∼85% excluding the N terminal extension of ACC2) and have the same domain structure responsible for enzyme activity.”
The paper relies on this without support.
Acc1 is localized in the cytosol, where it regulates lipogenesis in the liver and adipose tissue.
“Acc1 is localized in the cytosol, where it is thought to regulate lipogenesis in the liver and adipose tissue.”
The paper relies on this without support.
CPT1 regulates the transfer of long-chain acyl-CoAs from the cytosol into the mitochondria, where they are oxidized.
“CPT1 regulates the transfer of long-chain acyl-CoAs (LCCoAs) from the cytosol into the mitochondria, where they are oxidized.”
The paper relies on this without support.
Insulin resistance is a key element in the pathogenesis of type 2 diabetes and the metabolic syndrome.
“Insulin resistance is in turn a key element in the pathogenesis of type 2 diabetes and the metabolic syndrome.”
The paper relies on this without support.
Acc2 regulates malonyl-CoA levels in the immediate proximity of CPT1.
“which is believed to regulate malonyl-CoA levels in the immediate proximity of CPT1.”
The paper relies on this without support.
PEPCK and G6P are key regulators of hepatic glucose production.
“PEPCK and G6P are key regulators of HGP”
The paper relies on this without support.
Insulin suppresses endogenous glucose production, at least in part, by lowering mRNA levels of PEPCK and G6P.
“insulin suppresses endogenous glucose production, at least in part, by lowering mRNA levels of PEPCK and G6P.”
The paper relies on this without support.
Acc catalyzes a key rate-controlling step in both de novo lipogenesis and fatty acid oxidation.
“Acc catalyzes a key rate-controlling step in both de novo lipogenesis and fatty acid oxidation.”
The paper relies on this without support.
Plasma ketones are synthesized in the liver from acetyl-CoA derived from fatty acid oxidation and can be used as an indirect marker of hepatic fatty acid oxidation.
“Plasma ketones are synthesized in the liver from acetyl-CoA derived from fatty acid oxidation and can, therefore, be used as an indirect marker of hepatic fatty acid oxidation.”
The paper relies on this without support.
The hypothesis that cytosolic Acc1 regulates malonyl-CoA synthesis for incorporation into fatty acids, whereas Acc2 regulates mitochondrial fatty acid oxidation, has never been directly tested.
“this hypothesis has never been directly tested”
The paper relies on this without support.
The rat high-fat diet model of hepatic steatosis and insulin resistance is predictive of human NAFLD and hepatic insulin resistance.
“Thus, hepatic Acc1 and -2 inhibitors may be useful in the treatment of NAFLD and hepatic insulin resistance.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“recent studies have demonstrated that NAFLD-induced hepatic insulin resistance is a major factor responsible for the transition from normoglycemia to fasting hyperglycemia and T2DM (18–23).”
From The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome (2007) · cites this paper as [23]
In the citing paper
“NAFLD is strongly linked to hepatic insulin resistance”
From The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome (2007) · cites this paper as [23]
In the citing paper
“There is now strong evidence that nonalcoholic fatty liver disease has an important role in causing hepatic insulin resistance.1–3,23–27”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [26]
In the citing paper
“Recent studies have shown that increased hepatocellular concentrations of diacylglycerol in nonalcoholic fatty liver disease lead to activation of the protein kinase C epsilon isoform, resulting in reduced insulin signaling and hepatic insulin resistance.23–27”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [26]
In the citing paper
“In this setting, PKCε, but not other isoforms of PKC, is activated.”
From Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease (2007) · cites this paper as [12]
In the citing paper
“Preventing fat accumulation by inhibiting lipid synthesis via disruption of the mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase (7) or promoting fat oxidation using either the mitochondrial uncoupler 2,4-dinitrophenol (10) or inhibition of acetyl-CoA carboxylase-1 and -2 (12) prevents PKCε activation and hepatic insulin resistance.”
From Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease (2007) · cites this paper as [12]
In the citing paper
“Preventing fat accumulation in rodents preserves hepatic insulin action (7,10,12).”
From Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease (2007) · cites this paper as [12]
In the citing paper
“This is important since DAG is a known activator of classic and novel isoforms of PKC and DAG concentrations have closely paralleled insulin resistance in other models (7,12).”
From Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease (2007) · cites this paper as [12]
In the citing paper
“This is important since DAG is a known activator of classic and novel isoforms of PKC and DAG concentrations have closely paralleled insulin resistance in other models (7,12).”
From Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease (2007) · cites this paper as [12]
In the citing paper
“There is increasing evidence for a causal relationship between hepatic steatosis and hepatic insulin resistance both in rodent models with hepatic steatosis and in patients with nonalcoholic fatty liver disease (4, 18-25).”
From Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men (2006) · cites this paper as [25]
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Mechanism of activation of protein kinase B by insulin and IGF‐1.
Alessi, D. R., Andjelković, M., Caudwell, B., Cron, P. D., MORRICE, N. A., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,014
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Flagged first, then by citations
3 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 449
Imai, Y., Varela, G. M., Jackson, M. B., Graham, M. J., Crooke, R. M., & Ahima, R. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.046 · Cited by 165
Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond
Sun, Q., Karwi, Q. G., Wong, N. K. P., & Lopaschuk, G. D. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae231 · Cited by 164
High Fat Feeding Induces Hepatic Fatty Acid Elongation in Mice
Oosterveer, M. H., van Dijk, T. H., Tietge, U. J. F., Boer, T. S., Havinga, R., Stellaard, F., Groen, A. K., Kuipers, F., & Reijngoud, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006066 · Cited by 165
Hoehn, K. L., Turner, N., Swarbrick, M. M., Wilks, D., Preston, E., Phua, Y., Joshi, H., Furler, S. M., Larance, M., Hegarty, B. D., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.008 · Cited by 156
Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter
Lodhi, I. J., Wei, X., & Semenkovich, C. F. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.09.002 · Cited by 160
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 166
Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging
Gong, Z., Tas, E., Yakar, S., & Muzumdar, R. H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.12.022 · Cited by 153
Cunha, G. M., Guzmán, G., Mello, L. L. C. D., Trein, B., Spina, L. D. C., Bussade, I., Prata, J. M., Sajoux, I., & Countinho, W. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00607 · Cited by 149
Gambino, R., Musso, G., & Cassader, M. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.3058 · Cited by 147
Tang, G., Xu, Y., Zhang, C., Wang, N., Li, H., & Feng, Y. (2021) · Antioxidants · doi:10.3390/antiox10071076 · Cited by 150
Jurczak, M. J., Lee, A., Jornayvaz, F. R., Lee, H., Birkenfeld, A. L., Guigni, B. A., Kahn, M., Samuel, V. T., Glimcher, L. H., & Shulman, G. I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316760 · Cited by 143
Ren, L., Chan, S. M. H., Zeng, X., Laybutt, D. R., Iseli, T. J., Sun, R., Kraegen, E. W., Cooney, G. J., Turner, N. A., & Ye, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030816 · Cited by 143
Herbal medicines and nonalcoholic fatty liver disease
Yao, H., Qiao, Y.-J., Ya-li, Z., Tao, X., Xu, L., Yin, L., Qi, Y., & Peng, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6890 · Cited by 141
Orellana-Gavaldà, J. M., Herrero, L., Malandrino, M. I., Pañeda, A., Sol Rodríguez-Peña, M., Petry, H., Asins, G., Van Deventer, S., Hegardt, F. G., & Serra, D. (2011) · Hepatology · doi:10.1002/hep.24140 · Cited by 135
NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects
Sliz, E., Sebert, S. P., Würtz, P., Kangas, A. J., Soininen, P., Lehtimäki, T. J., Kähönen, M. A. P., Viikari, J. S. A., Männikkö, M., Ala‐Korpela, M., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy124 · Cited by 138
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 136
Therapeutic potential of green tea in nonalcoholic fatty liver disease
Masterjohn, C. M., & Bruno, R. S. (2012) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00440.x · Cited by 132
Syed‐Abdul, M. M., Parks, E. J., Gaballah, A. H., Bingham, K., Hammoud, G. M., Kemble, G. W., BUCKLEY, D. I., McCulloch, W. F., & Manrique‐Acevedo, C. (2019) · Hepatology · doi:10.1002/hep.31000 · Cited by 131
Hepatic De Novo Lipogenesis Is Present in Liver-Specific ACC1-Deficient Mice
Harada, N., Oda, Z., Hara, Y., Fujinami, K., Okawa, M., Ohbuchi, K., Yonemoto, M., Ikeda, Y., Ohwaki, K., Aragane, K., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01122-06 · Cited by 132
Zhang, J., Zhang, W., Yang, L. H., Zhao, W., Liu, Z., Wang, E., & Wang, J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154589 · Cited by 131
Jornayvaz, F. R., Samuel, V. T., & Shulman, G. I. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104726 · Cited by 132
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
Finck, B. N. (2018) · Diabetes · doi:10.2337/dbi18-0024 · Cited by 125
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
Esler, W. P., & Cohen, D. E. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.042 · Cited by 122
MASH: the nexus of metabolism, inflammation, and fibrosis
Steinberg, G. R., Carpentier, A. C., & Wang, D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186420 · Cited by 135
Dulloo, A. G. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00909.x · Cited by 125
Talukdar, S., & Hillgartner, F. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600276-jlr200 · Cited by 128
Fatty liver: Role of inflammation and fatty acid nutrition
Byrne, C. D. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.02.012 · Cited by 119
Liver fat and lipid oxidation in humans
Kotronen, A., Seppälä‐Lindroos, A., Vehkavaara, S., Bergholm, R., Frayn, K. N., Fielding, B. A., & Yki‐Järvinen, H. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02076.x · Cited by 120
Croci, I., Byrne, N. M., Choquette, S., Hills, A. P., Chachay, V., Clouston, A. D., O'Moore‐Sullivan, T. M., Macdonald, G. A., Prins, J. B., & Hickman, I. J. (2012) · Gut · doi:10.1136/gutjnl-2012-302789 · Cited by 119
Inhibition of ADRP prevents diet-induced insulin resistance
Varela, G. M., Antwi, D. A., Dhir, R. N., Yin, X., Singhal, N. S., Graham, M. J., Crooke, R. M., & Ahima, R. S. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90204.2008 · Cited by 113
Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake
Olson, D. P., Pulinilkunnil, T., Cline, G. W., Shulman, G. I., & Lowell, B. B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913492107 · Cited by 109
Chow, J. D. Y., Lawrence, R., Healy, M. E., Dominy, J. E., Liao, J. A., Breen, D. S., Byrne, F. L., Kenwood, B. M., Lackner, C., Okutsu, S., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.004 · Cited by 111
Xian, Y., Weng, J., & Xu, F. L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001263 · Cited by 111
Kursawe, R., Caprio, S., Giannini, C., Narayan, D., Lin, A., D’Adamo, E., Shaw, M. M., Pierpont, B. M., Cushman, S. W., & Shulman, G. I. (2012) · Diabetes · doi:10.2337/db12-0889 · Cited by 109
Ins and Outs Modulating Hepatic Triglyceride and Development of Nonalcoholic Fatty Liver Disease
Goldberg, I. J., & Ginsberg, H. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.040 · Cited by 99
Specific protein kinase C isoforms as transducers and modulators of insulin signaling
SAMPSON, S., & COOPER, D. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.04.017 · Cited by 97
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross, T. T., Crowley, C., Kelly, K. L., Rinaldi, A., Beebe, D. A., Lech, M. P., Martinez, R. V., Carvajal-Gonzalez, S., Boucher, M., Hirenallur-Shanthappa, D., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.06.001 · Cited by 94
Monsénégo, J., Mansouri, A., Akkaoui, M., Lenoir, V., Esnous, C., Fauveau, V., Tavernier, V., Girard, J., & Prip-Buus, C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.008 · Cited by 91
Hwang, S., Jeong, Y., Li, X., Kim, Y. D., Lu, Y., Chang, Y., Lee, I., & Chang, H. W. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12124 · Cited by 92
Metabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin
Yee, L. D., Mortimer, J. E., Natarajan, R. D., Dietze, E. C., & Seewaldt, V. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00058 · Cited by 98
Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice #
Zhao, H., Przybylska, M., Wu, I., Zhang, J., Maniatis, P., Pacheco, J., Piepenhagen, P. A., Copeland, D., ARBEENY, C. M., Shayman, J. A., et al. (2009) · Hepatology · doi:10.1002/hep.22970 · Cited by 89
Mechanisms Preserving Insulin Action during High Dietary Fat Intake
Lundsgaard, A., Holm, J. B., Sjøberg, K. A., Bojsen-Møller, K. N., Myrmel, L. S., Fjære, E., Jensen, B. A. H., Nicolaisen, T. S., Hingst, J. R., Hansen, S. L., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.022 · Cited by 85
Wan, J., Zhang, Y., Yang, D., Liang, Y., Yang, L., Hu, S., Liu, Z., Fang, Q., Tian, S., & Ding, Y. (2021) · Hepatology · doi:10.1002/hep.32068 · Cited by 85
Zhang, D., Christianson, J., Liu, Z., Tian, L., Choi, C. S., Neschen, S., Dong, J., Wood, P. A., & Shulman, G. I. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.012 · Cited by 84
Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice
Carr, R. M., Patel, R. T., Rao, V., Dhir, R. N., Graham, M. J., Crooke, R. M., & Ahima, R. S. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00177.2011 · Cited by 83
Petito‐da‐Silva, T. I., Souza‐Mello, V., & Barbosa‐da‐Silva, S. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110539 · Cited by 82
Szymczak-Pajor, I., Wenclewska, S., & Śliwińska, A. (2022) · Pharmaceuticals · doi:10.3390/ph15070810 · Cited by 89
Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
Yao, C., Dai, S., Wang, C., Fu, K., Wu, R. X., Zhao, X., Yao, Y., & Li, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115464 · Cited by 82
Time‐dependent effects of fatty acids on skeletal muscle metabolism
Hirabara, S. M., Silveira, L. R., Abdulkader, F., Carvalho, C. R. D. O., Procópio, J., & Curi, R. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20811 · Cited by 80
The Heterogeneity of Lipid Metabolism in Cancer
Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_3 · Cited by 80
Understanding Metabolic Homeostasis and Imbalance: What Is the Role of the Endocannabinoid System?
Kunos, G. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.007 · Cited by 79
Role of Pyruvate Dehydrogenase Kinase 4 in Regulation of Blood Glucose Levels
Jeoung, N. H., & Harris, R. A. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.5.274 · Cited by 79
Pathophysiology of NASH in endocrine diseases
Gariani, K., & Jornayvaz, F. R. (2021) · Endocrine Connections · doi:10.1530/ec-20-0490 · Cited by 77
Postprandial Lipemia Associates with Liver Fat Content
Matikainen, N., Mänttäri, S., Westerbacka, J., Vehkavaara, S., Lundbom, N. M. I., Yki‐Järvinen, H., & Taskinen, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0187 · Cited by 76
Goedeke, L., Perry, R. J., & Shulman, G. I. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104727 · Cited by 76
Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer
Zhao, J., Xu, L., Meng, D., Zeng, L., Zhuang, R., Huang, S., Lv, W., & Hu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578315 · Cited by 73
Watanabe, C., Seino, Y., Miyahira, H., Yamamoto, M., Fukami, A., Ozaki, N., Takagishi, Y., Sato, J., Fukuwatari, T., Shibata, K., et al. (2011) · Diabetes · doi:10.2337/db11-0739 · Cited by 70
Wang, Q. A., Li, S., Jiang, L., Zhou, Y., Li, Z., Shao, M., Li, W., & Liu, Y. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003335 · Cited by 70
Yin, Y., Gao, L., Lin, H., Wu, Y., Han, X., Zhu, Y., & Li, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.101 · Cited by 68
Abel, R., Mondal, S., Masse, C. E., Greenwood, J. R., Harriman, G. C. B., Ashwell, M. A., Bhat, S., Wester, R. T., Frye, L. L., Kapeller, R., et al. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.10.007 · Cited by 68
Eckel, R. H. (2007) · Proceedings of The Nutrition Society · doi:10.1017/s0029665107005320 · Cited by 69
Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease
Dong, H., Lu, F., & Zhao, L. (2012) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-012-0993-2 · Cited by 67
Dahl, G. E. (2008) · Journal of Animal Science · doi:10.2527/jas.2007-0311 · Cited by 67
Akkaoui, M., Cohen, I., Esnous, C., Lenoir, V., Sournac, M., Girard, J. R., & Prip‐Buus, C. (2009) · Biochemical Journal · doi:10.1042/bj20081932 · Cited by 66
Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity
Poudyal, H., & Brown, L. (2011) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153011796429826 · Cited by 67
Anthocyanins Inhibit Lipogenesis During Adipocyte Differentiation of 3T3-L1 Preadipocytes
Lee, B., Lee, M., Lefevre, M., & Kim, H. (2014) · Plant Foods for Human Nutrition · doi:10.1007/s11130-014-0407-z · Cited by 64
Fondevila, M. F., Fernandez, U., Gonzalez-Rellan, M. J., Lima, N. D. S., Buqué, X., González‐Rodríguez, Á., Alonso, C., Iruarrizaga‐Lejarreta, M., Delgado, T. C., Varela‐Rey, M., et al. (2020) · Hepatology · doi:10.1002/hep.31290 · Cited by 64
Wendel, A. A., Li, L. O., Li, Y., Cline, G. W., Shulman, G. I., & Coleman, R. A. (2010) · Diabetes · doi:10.2337/db09-1380 · Cited by 63
Amrutkar, M., Cansby, E., Chursa, U., Nuñez‐Durán, E., Chanclón, B., Ståhlman, M., Fridén, V., Mannerås-Holm, L., Wickman, A., Smith, U., et al. (2015) · Diabetes · doi:10.2337/db15-0060 · Cited by 63
Perry, R. J., Peng, L., Cline, G. W., Butrico, G. M., Wang, Y., Zhang, X., Rothman, D. L., Petersen, K. F., & Shulman, G. I. (2017) · Nature Communications · doi:10.1038/s41467-017-01143-w · Cited by 61
Lê, K.-A., & Bortolotti, M. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f3ec · Cited by 60
Camporez, J. P., Kanda, S., Petersen, M. C., Jornayvaz, F. R., Samuel, V. T., Bhanot, S., Petersen, K. F., Jurczak, M. J., & Shulman, G. I. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m054080 · Cited by 61
Zizola, C. F., Schwartz, G. J., & Vogel, S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90464.2008 · Cited by 61
Leem, J., & Koh, E. H. (2011) · Experimental Diabetes Research · doi:10.1155/2012/242984 · Cited by 62
A Balance of Lipid-Sensing Mechanisms in the Brain and Liver
Caspi, L., Wang, P. Y. T., & Lam, T. K. T. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.005 · Cited by 58
Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation
Li, H., Zheng, J., Xu, Q., Yang, Y., Zhou, J., Guo, X., Cai, Y., Cai, J. J., Xie, L., Awika, J. M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.09.027 · Cited by 58
Gu, Y. G., Weitzberg, M., Clark, R. F., Xu, X., Li, Q., Zhang, T., Hansen, T. M., Liu, G., Xin, Z., Wang, X., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060484v · Cited by 59
Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice
Luo, L., Fang, K., Dan, X., & Gu, M. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-018-0955-6 · Cited by 56
Understanding the Multiple Effects of PCBs on Lipid Metabolism
Shan, Q., Li, H., Chen, N., Qu, F., & Guo, J. H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s264851 · Cited by 59
Gao, X., Chen, T., Zhou, F., Sun, Y., Zhang, J., Li, X., Zhao, W., Li, Y., Shi, Y., Niu, K., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02758-w · Cited by 55
Lipid bilayer stress in obesity-linked inflammatory and metabolic disorders
Gianfrancesco, M. A., Paquot, N., Piette, J. G., & Legrand-Poels, S. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.022 · Cited by 61
Recent Development in Acetyl-CoA Carboxylase Inhibitors and their Potential as Novel Drugs
Wu, X., & Huang, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0312 · Cited by 55
Freeman‐Cook, K. D., Amor, P. A., Bader, S. J., Buzon, L. M., Coffey, S. B., Corbett, J. W., DiRico, K. J., Doran, S. D., Elliott, R. L., Esler, W. P., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201503u · Cited by 55
Chen, Y., Varghese, Z., & Ruan, X. Z. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.007 · Cited by 54
Kampe, K., Sieber, J., Orellana, J. M., Mundel, P. H., & Jehle, A. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00454.2013 · Cited by 56
Chemical Genetics of Acetyl-CoA Carboxylases
Zu, X., Zhong, J., Luo, D., Tan, J., Zhang, Q., Wu, Y., Liu, J., Cao, R., Wen, G., & Cao, D. (2013) · Molecules · doi:10.3390/molecules18021704 · Cited by 54
Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats
Rodrı́guez, A., Catalán, V., Becerril, S., Gil, M. J., Mugueta, C., Gómez‐Ambrosi, J., & Frühbeck, G. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.07.022 · Cited by 53
Glatzel, D., Koeberle, A., Pein, H., Loeser, K., Stark, A., Keksel, N., Werz, O., Müller, R., Bischoff, I., & Fürst, R. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m080101 · Cited by 54
Mitochondria mediated cell death in diabetes
Szabadkai, G., & Duchen, M. R. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0363-5 · Cited by 54
Cui, C.-X., Deng, J., Yan, L., Liu, Y., Fan, J., Mu, H., Sun, H., Wang, Y.-H., & Han, J. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.06.030 · Cited by 51
Wu, Y., Wang, M., Yang, T., Qin, L., Hu, Y.-M., Zhao, D., Wu, L., & Liu, T. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9561613 · Cited by 50
Tumor Progression Locus 2 (TPL2) Regulates Obesity-Associated Inflammation and Insulin Resistance
Perfield, J. W., Lee, Y., Shulman, G. I., Samuel, V. T., Jurczak, M. J., Chang, E., Xie, C., Tsichlis, P. N., Obin, M. S., & Greenberg, A. S. (2011) · Diabetes · doi:10.2337/db10-0715 · Cited by 52
Wei, S., Zhang, M., Yu, Y., Xue, H., Lan, X., Liu, S., Hatch, G. M., & Chen, L. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.038 · Cited by 51
Changes in body composition and metabolic disease risk
Pi-Sunyer, X. (2018) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0320-x · Cited by 53
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52
Griffith, D. A., Dow, R. L., Huard, K., Edmonds, D. J., Bagley, S. W., Polívková, J., Zeng, D., García-Irizarry, C. N., Southers, J. A., Esler, W. P., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401033t · Cited by 49
Cansby, E., Nuñez‐Durán, E., Magnusson, E., Amrutkar, M., Booten, S. L., Kulkarni, N. M., Svensson, T., Borén, J., Marschall, H., Aghajan, M., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.12.004 · Cited by 50
Ashworth, W. B., Davies, N. A., & Bogle, I. D. L. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005105 · Cited by 50
Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism
Abruzzese, G. A., Heber, M. F., Ferreira, S. R., Vélez, L. M., Reynoso, R., Pignataro, O. P., & Motta, A. B. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0471 · Cited by 48
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?
Finck, B. N., & Hall, A. M. (2015) · BioMed Research International · doi:10.1155/2015/104132 · Cited by 47
Metadata
- Authors
- Savage, D. B.
- Affiliations
- Yale University (US)
- Corresponding author
- Savage, D. B.
- ORCID
- Savage, D. B.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 817-824
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1366503
- OpenAlex
- W2168436114
- Semantic Scholar
- b60a71456837361b15d6f178e59b8779765b0f90
- Cited by
- 447
- References
- 48
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 13 · 2023: 17 · 2022: 21 · 2021: 17 · 2020: 25 · 2019: 14 · 2018: 27 · 2017: 17 · 2016: 27 · 2015: 20 · 2014: 27 · 2013: 21 · 2012: 28
- FWCI
- 23.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- American Diabetes Association
- Wellcome Trust
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- acetyl-CoA carboxylase 1, acetyl-CoA carboxylase 2, antisense oligonucleotides, hepatic steatosis, non-alcoholic fatty liver disease, hepatic insulin resistance, malonyl-CoA, fatty acid oxidation, lipogenesis, metabolic syndrome, type 2 diabetes, plasma ketones, hepatocytes
- MeSH terms
- Acetyl-CoA Carboxylase, Animals, Diet, Enzyme Inhibitors, Fatty Acids, Fatty Liver, Insulin Resistance, Triglycerides, Signal Transduction, Oligonucleotides, Antisense, Hepatocytes, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
